Spike Protein News and Research

RSS

Prion-like domains in SARS-CoV-2 RBD and ACE2 play important functional roles in viral adhesion and entry

Scientists have recently detected and analyzed viral PrDs in the S protein of SARS-CoV-2, which are the novel regulators of virion assembly.

31 Jan 2022

Binding and conformational properties of the SARS-CoV spike protein and hACE2 complex

A new paper in the journal Molecules describes this in molecular terms, comparing SARS-CoV-2 with an earlier highly pathogenic coronavirus, SARS-CoV.

31 Jan 2022

Research shows minks mimic severe COVID-19 symptoms, including ARDS

Minks may be a suitable animal model for testing severe COVID-19 infections, finds a recent bioRxiv* preprint study. While mice and ferrets are used in preclinical severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is currently no model specific to severe disease.

30 Jan 2022

Immunity based upon “mild" Omicron infection is weak for Omicron reinfection

Researchers evaluate antibody responses in vaccinated individuals who subsequently developed Delta and Omicron SARS-CoV-2 breakthrough infections.

30 Jan 2022

Imaging microscopy shows killer T-cells targeting SARS-CoV-2 spike protein

Researchers demonstrate how cytotoxic T-lymphocytes (CTLs) with specificity for SARS-CoV-2 eliminate multiple infected targets.

30 Jan 2022

Mix-and-match of COVID-19 vaccine boosters found to be safe and effective

In adults who had previously received a full regimen of a COVID-19 vaccine approved or authorized by the Food and Drug Administration (FDA), an additional dose of any of these COVID-19 vaccines was safe and prompted an immune response, according to study findings published Jan. 26 in The New England Journal of Medicine.

28 Jan 2022

Novel “prime and spike” vaccine strategy leverages existing immunity generated by primary COVID-19 vaccination

Scientists from Yale University, USA, have recently developed an intranasal spike boosting vaccine that induces robust mucosal immunity in the respiratory tract,

28 Jan 2022

Reduced neutralization against Omicron variant in fully immunized adolescents with BNT162b2 vaccine

Researchers compare the humoral immune response in adolescents and adults after being completely immunized with the Pfizer BNT162b2 vaccine.

28 Jan 2022

Potential therapy candidates for patients infected with the SARS-CoV-2 Omicron variant

Researcher discusses several promising therapeutic candidates that have been proposed for the treatment of patients infected with the Omicron variant.

28 Jan 2022

Study demonstrates minimally invasive, aerosolized vaccine candidate to combat SARS-CoV-2

This study showed inhalable Covid-19 mimetic particle carriers as potential, versatile, aerosolizable COVID-19 vaccine candidates if worked on with continued optimization and refinement.

28 Jan 2022

Magnetic nanoparticles for SARS-CoV-2 and other virus detection systems

Researchers discuss the contributions that have been provided by magnetic nanoparticles for the molecular diagnosis of human viruses.

28 Jan 2022

Exploring receptor-blocking conserved non-neutralizing antibodies for SARS-CoV-2 therapy

In a new study, researchers hypothesized and developed broad-spectrum SARS-CoV-2 inhibitors, ReconnAbs, by modifying the existing non-neutralizing antibodies targeted towards the highly conserved epitopes of the SARS-CoV-2 spike (S) protein combined with a receptor-blocking component.

28 Jan 2022

Early-stage alveolar epithelial cell necrosis linked to COVID-19-induced acute respiratory distress syndrome

A new study analyzed whether alveolar epithelial cell necrosis at an early stage SARS-CoV-2 infection and subsequent releases of damage-associated molecular patterns could aggravate COVID-19-associated acute respiratory distress syndrome.

27 Jan 2022

Scientists identify immunogens that can elicit antibody responses against multiple SARS-CoV-2 variants

In a new study, researchers identified conserved sites in the SARS-CoV-2 spike protein using structural and sequence data, and then combined the results with existing deep mutational scanning data to design six antigens that can offer protection against significant immune escape mutations in the SARS-CoV-2 receptor-binding domain.

27 Jan 2022

SARS-CoV-2 mutations and their impact on spike protein-specific T lymphocytes

New research assesses the impact of mutations in SARS-CoV-2 variants of concern (VOCs) on the T lymphocytes, specifically to the spike (S) protein of SARS-CoV-2.

27 Jan 2022

Study suggests enhanced phosphorylation and increased abundance of SARS-CoV-2 nucleocapsid protein provide selective advantage

Researchers have been investigating the phosphorylation of the nucleocapsid protein.

27 Jan 2022

French project takes an extra step in the development of nasal vaccine candidate against COVID-19

The development of a protein vaccine candidate for nasal administration has taken another step. Led by the BioMAP research team, from the Infectiology and Public Health (ISP) joint research unit run by INRAE and the Université de Tours, this project, supported by the Ministry of Higher Education, Research and Innovation, and accompanied by the ANRS | Maladies infectieuses émergentes, is moving up a gear.

27 Jan 2022

Omicron RBD mutations increase ACE2 binding and reduce antibody sensitivity

In a study conducted at the Florida International University, USA, scientists have investigated the impact of spike receptor-binding domain (RBD) mutations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron variant on its interaction with human angiotensin-converting enzyme 2 (ACE2).

26 Jan 2022

New research on SARS-CoV-2 Omicron and care home residents

Researchers find a reduced risk of hospitalizations and deaths in long term care facility residents infected with SARS-CoV-2 Omicron variant.

26 Jan 2022

The new Omicron subvariant BA.2: what we know so far

Presently, an Omicron subvariant known as BA.2, first identified in late 2021, has made headlines due to its rapid spread.

26 Jan 2022

Spike Protein News and Research

Prion-like domains in SARS-CoV-2 RBD and ACE2 play important functional roles in viral adhesion and entry

Binding and conformational properties of the SARS-CoV spike protein and hACE2 complex

Research shows minks mimic severe COVID-19 symptoms, including ARDS

Immunity based upon “mild" Omicron infection is weak for Omicron reinfection

Imaging microscopy shows killer T-cells targeting SARS-CoV-2 spike protein

Mix-and-match of COVID-19 vaccine boosters found to be safe and effective

Novel “prime and spike” vaccine strategy leverages existing immunity generated by primary COVID-19 vaccination

Reduced neutralization against Omicron variant in fully immunized adolescents with BNT162b2 vaccine

Potential therapy candidates for patients infected with the SARS-CoV-2 Omicron variant

Study demonstrates minimally invasive, aerosolized vaccine candidate to combat SARS-CoV-2

Magnetic nanoparticles for SARS-CoV-2 and other virus detection systems

Exploring receptor-blocking conserved non-neutralizing antibodies for SARS-CoV-2 therapy

Early-stage alveolar epithelial cell necrosis linked to COVID-19-induced acute respiratory distress syndrome

Scientists identify immunogens that can elicit antibody responses against multiple SARS-CoV-2 variants

SARS-CoV-2 mutations and their impact on spike protein-specific T lymphocytes

Study suggests enhanced phosphorylation and increased abundance of SARS-CoV-2 nucleocapsid protein provide selective advantage

French project takes an extra step in the development of nasal vaccine candidate against COVID-19

Omicron RBD mutations increase ACE2 binding and reduce antibody sensitivity

New research on SARS-CoV-2 Omicron and care home residents

The new Omicron subvariant BA.2: what we know so far

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News